Johnson & Johnson（JNJ）財務資料JNJJohnson & Johnson

Johnson & Johnson (JNJ) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Oncology-DARZALEX, accounting for 116.6% of total sales, equivalent to $29.52B. Other significant revenue streams include Immunology-TREMFYA and MedTech-Cardiovascular-ELECTROPHYSIOLOGY. Understanding this composition is critical for investors evaluating how JNJ navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Johnson & Johnson maintains a gross margin of 68.17%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 25.49%, while the net margin is 0.83%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively JNJ converts its operational activities into shareholder value.

In the context of the broader market, JNJ competes directly with industry leaders such as ABBV and MRK. With a market capitalization of $610.38B, it holds a leading position in the sector. When comparing efficiency, JNJ's gross margin of 68.17% stands against ABBV's 74.74% and MRK's 74.64%. Such benchmarking helps identify whether Johnson & Johnson is trading at a premium or discount relative to its financial performance.

Johnson & Johnson reported a revenue of $25.4 billion for Q3 2026, a 5.9% increase year-over-year, and an adjusted EPS of $2.59, which was a slight decline of 7.5% from the previous year, showing resilience despite challenges in its medtech division.